整理 | GLP1减重宝典内容团队4月26日,广东东阳光药业股份有限公司和东莞市东阳光生物药研发有限公司自主研发的1类创新药HEC-007注射液已获国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》,批准HEC-007注射液开展2型糖尿病以及超重或肥胖两项适应症的临床试验,目前国内外尚无同类产品获批上市。HEC-007注射液是一种脂肪酸侧链修饰GLP-1/GCG/GIP三靶点多肽...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.